PMID- 23200817
OWN - NLM
STAT- MEDLINE
DCOM- 20130422
LR  - 20220408
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 85
IP  - 4
DP  - 2013 Mar 15
TI  - Involved node radiation therapy: an effective alternative in early-stage hodgkin 
      lymphoma.
PG  - 1057-65
LID - S0360-3016(12)03508-0 [pii]
LID - 10.1016/j.ijrobp.2012.08.041 [doi]
AB  - PURPOSE: The involved node radiation therapy (INRT) strategy was introduced for 
      patients with Hodgkin lymphoma (HL) to reduce the risk of late effects. With 
      INRT, only the originally involved lymph nodes are irradiated. We present 
      treatment outcome in a retrospective analysis using this strategy in a cohort of 
      97 clinical stage I-II HL patients. METHODS AND MATERIALS: Patients were staged 
      with positron emission tomography/computed tomography scans, treated with 
      adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy, and given INRT 
      (prechemotherapy involved nodes to 30 Gy, residual masses to 36 Gy). Patients 
      attended regular follow-up visits until 5 years after therapy. RESULTS: The 
      4-year freedom from disease progression was 96.4% (95% confidence interval: 
      92.4%-100.4%), median follow-up of 50 months (range: 4-71 months). Three relapses 
      occurred: 2 within the previous radiation field, and 1 in a previously uninvolved 
      region. The 4-year overall survival was 94% (95% confidence interval: 
      88.8%-99.1%), median follow-up of 58 months (range: 4-91 months). Early radiation 
      therapy toxicity was limited to grade 1 (23.4%) and grade 2 (13.8%). During 
      follow-up, 8 patients died, none from HL, 7 malignancies were diagnosed, and 5 
      patients developed heart disease. CONCLUSIONS: INRT offers excellent tumor 
      control and represents an effective alternative to more extended radiation 
      therapy in the combined modality treatment for early-stage HL.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Maraldo, Maja V
AU  - Maraldo MV
AD  - Department of Radiation Oncology, The Finsen Center, Rigshospitalet, Copenhagen, 
      Denmark. dra.maraldo@gmail.com
FAU - Aznar, Marianne C
AU  - Aznar MC
FAU - Vogelius, Ivan R
AU  - Vogelius IR
FAU - Petersen, Peter M
AU  - Petersen PM
FAU - Specht, Lena
AU  - Specht L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121129
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Cohort Studies
MH  - Combined Modality Therapy/methods
MH  - Dacarbazine/administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Heart Diseases/etiology
MH  - Hodgkin Disease/drug therapy/mortality/pathology/*radiotherapy
MH  - Humans
MH  - Lymphatic Irradiation/adverse effects/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Radiation Injuries/pathology
MH  - Radiotherapy Dosage
MH  - Recurrence
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage
MH  - Young Adult
EDAT- 2012/12/04 06:00
MHDA- 2013/04/23 06:00
CRDT- 2012/12/04 06:00
PHST- 2012/07/25 00:00 [received]
PHST- 2012/08/30 00:00 [revised]
PHST- 2012/08/30 00:00 [accepted]
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - S0360-3016(12)03508-0 [pii]
AID - 10.1016/j.ijrobp.2012.08.041 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1057-65. doi: 
      10.1016/j.ijrobp.2012.08.041. Epub 2012 Nov 29.